CANCER MEDICINES IN DEVELOPMENT
The fourth survey of "New Medicines in Development for Older Americans" by the US Pharmaceutical Manufacturers Association reports that there are more medicines in development for cancer than for any other disease of aging, at 124 in total (see table for 31 drugs now in Phase III).
During the present year, 49 research-based pharmaceutical companies and the National Cancer Institute are developing drugs for 17 cancers and related conditions. The report notes that many of the products are being developed for more than one type of cancer.
Biotechnology continues to play a significant role in the research cancer treatments, according to the PMA. At least 16 of the cancer medicines in development involve genetic engineered medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze